SK Life Science
SK Life Science sponsors 25 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 21 completed. 6 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Partial Epilepsy, with 2 trials.
Trial Pipeline
25 total, page 1 of 1
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
NCT05219617
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
NCT05067634
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213
A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally
NCT05572255
Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
NCT05388435
Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures
NCT04903314
Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet
NCT04690751
Bioavailability and Food Effect Study of 3 Types of Carisbamate
NCT04520360
Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects
NCT04505397
Cenobamate Open-Label Extension Study for YKP3089C025
NCT03961568
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
NCT04062981
Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
NCT03731715
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
NCT03678753
A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users
NCT03509285
Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions
NCT03234699
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
NCT02535091
A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
NCT02205099
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation
NCT01989234
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
NCT01866111
A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation
NCT01523184
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study for the Pain of Diabetic Peripheral Neuropathy
NCT01521598
Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
NCT01397968
Efficacy of YKP3089 in Patients With Photosensitive Epilepsy
NCT00616148
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
NCT00228969
A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
NCT00109083
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 8 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Therapeutic Areas
What the Pipeline for SK Life Science Shows
According to the ClinicalTrials.gov registry, SK Life Science is linked to 25 US clinical trials across every stage of research activity. Of those, 2 studies are currently recruiting, about 8% of the sponsor's indexed portfolio, and 21 are already marked complete, representing roughly 84% of the total.
The phase mix for SK Life Science reports 6 late-stage studies (Phase 3 and Phase 4 combined) and 19 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for SK Life Science is Partial Epilepsy with 2 linked trials, and 7 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.